US EditionPublished • loading... • Updated
Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Orthopaedic Foot & Ankle Society Annual Meeting
- Endo announced that two presentations about plantar fibromatosis and plantar fasciitis will be shared at the American Orthopaedic Foot & Ankle Society Annual Meeting from September 10-13, 2025.
- The presentations will discuss findings from Phase 1 and Phase 2 studies involving collagenase clostridium histolyticum in patients with plantar fasciitis and plantar fibromatosis.
- Endo is conducting a Phase 3 study to explore a potential nonsurgical treatment for plantar fibromatosis, reinforcing its commitment to medical advancements.
- Collagenase clostridium histolyticum is not approved for treating plantar fibromatosis or plantar fasciitis, and Endo is enrolling patients for the Phase 3 program.
Insights by Ground AI
31 Articles
31 Articles
Bennington Banner+30 Reposted by 30 other sources
Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Orthopaedic Foot & Ankle Society Annual Meeting
MALVERN, Pa., Sept. 10, 2025 /PRNewswire/ -- Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today that two presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared during the American Orthopaedic Foot & Ankle Society Annual…
Coverage Details
Total News Sources31
Leaning Left2Leaning Right3Center8Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
15%
C 62%
R 23%
Factuality
To view factuality data please Upgrade to Premium
